Akari Therapeutics PLC
AKTX—
Build a strategy around AKTX
Akari Therapeutics PLC AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with 2.5M cash vs 15.6M current liabilities - under 3 months runway at -9.7M annual burn rate[Cash and Equivalents]
- Intangibles (42.4M) are 187% of equity (22.7M) - tangible book value is NEGATIVE (-19.7M)[Tangible Book Value]
- 5.2M impairment charge TTM on 8.4M goodwill signals asset quality deterioration[Impairment of Capital Assets]
Watch Triggers
- Cash and Equivalents: Falls below 1.5M or capital raise announced — Sub-1.5M triggers going concern; financing terms determine dilution severity
- Total Revenue TTM: Any revenue recognition from partnerships/licensing — First revenue validates pipeline and extends runway without dilution
- Research and Development TTM: Significant increase or decrease from 3.0M baseline — Increase signals trial advancement; decrease signals cash preservation mode
Bull Case
PE of 2.1x vs industry median 26.7x with positive EPS (0.19) suggests extreme discount IF pipeline succeeds
PE RatioEPS TTM
R&D spend of 3.0M TTM (23% of opex) maintains pipeline optionality at minimal cost
Research and Development TTM
Bear Case
Zero revenue pre-clinical biotech with 2.5M cash cannot survive without imminent financing - severe dilution likely
Total Revenue TTMCash and EquivalentsFree Cash Flow TTM
Negative tangible equity (-19.7M) means equity holders have no asset protection in liquidation
Tangible Book ValueGoodwill and Other Intangible Assets
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
15%
Leverage AKTX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent dilution or restructuring required within 6 months given cash runway
3-12mhigh
- 2.5M cash vs 9.7M annual burn
- Zero capital stock issuance TTM
- Working capital deficit of -12.6M
FCF TTM: -9.7MCurrent ratio: 0.19xNo revenue to fund operations
Valuation Context
Caveats
AKTX Fundamentals
Professional, Scientific, and Technical Services → Professional, Scientific, and Technical Services
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$470.65B | — | ||
$470.65B | — | ||
0.00 | — | ||
$0 | — | ||
$0.00 | -4.9% | — | |
0% | — | ||
0% | — | ||
$-10.57M | — | ||
-68.4% | — | ||
Beta 5Y (Monthly) | unknown | — |
AKTX Dividend History
No dividends
AKTX Stock Splits
4 stock splits
03/31/2640:1 split
08/17/2320:1 split
09/17/1510:1 split
01/03/1410:1 split
AKTX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/30/26 | 12/31/25 | 10-K | |
11/13/25 | 09/30/25 | 10-Q | |
08/13/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
04/15/25 | 12/31/24 | Unknown | |
11/19/24 | 09/30/24 | 10-Q | |
08/19/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
03/29/24 | 12/31/23 | 10-K | |
11/19/24 | 09/30/23 | 10-Q | |
09/29/23 | 06/30/23 | 6-K | |
05/15/24 | 03/31/23 | 10-Q | |
09/27/22 | 06/30/22 | 6-K | |
07/20/22 | 03/31/22 | 6-K | |
05/16/22 | 12/31/21 | 20-F | |
05/01/23 | 12/31/21 | 20-F | |
12/03/21 | 09/30/21 | 6-K | |
09/22/21 | 06/30/21 | 6-K | |
06/29/21 | 03/31/21 | 6-K | |
04/21/21 | 12/31/20 | 20-F | |
05/01/23 | 12/31/20 | 20-F | |
12/11/20 | 09/30/20 | 6-K | |
09/01/20 | 06/30/20 | 6-K | |
05/29/20 | 03/31/20 | 6-K | |
03/31/20 | 12/31/19 | 20-F | |
11/27/19 | 09/30/19 | 6-K | |
08/29/19 | 06/30/19 | 6-K | |
05/29/19 | 03/31/19 | 6-K | |
04/23/19 | 12/31/18 | 20-F | |
11/15/18 | 09/30/18 | 6-K | |
09/28/18 | 06/30/18 | 6-K | |
08/17/18 | 03/31/18 | 6-K | |
07/18/18 | 12/31/17 | 20-F | |
11/13/17 | 09/30/17 | 6-K | |
08/10/17 | 06/30/17 | 6-K | |
05/15/17 | 03/31/17 | 6-K | |
03/31/17 | 12/31/16 | 20-F | |
11/10/16 | 09/30/16 | 6-K | |
08/11/16 | 06/30/16 | 6-K | |
05/12/16 | 03/31/16 | 10-Q | |
03/23/16 | 12/31/15 | 10-K | |
11/23/15 | 09/30/15 | 10-Q | |
08/12/15 | 06/30/15 | 10-Q | |
05/12/15 | 03/31/15 | 10-Q | |
02/11/15 | 12/31/14 | 10-K | |
11/23/15 | 09/30/14 | 10-Q | |
08/12/15 | 06/30/14 | 10-Q | |
05/12/15 | 03/31/14 | 10-Q |